Galvani Bioelectronics

What is Galvani Bioelectronics?

Galvani Bioelectronics is a joint venture between Verily and GlaxoSmithKline (GSK) created to enable the research, development and commercialization of bioelectronic medicines.

How are you making it happen?

Galvani Bioelectronics will bring together GSK’s drug discovery and development expertise and deep understanding of disease biology with Verily’s technical expertise in the miniaturization of low power electronics, device development, data analytics and software development for clinical application. Bioelectronic medicines will be designed to treat disease by modulating electrical signals in peripheral nerves using miniature, implanted devices. They may provide an entirely new toolkit for control and reversal of disease, and could complement pharmaceutical and other therapies. Galvani’s initial work will center on establishing clinical proof of principle in inflammatory, metabolic and endocrine disorders and developing miniaturized, precise devices.

Learn more in our newsroom